ACOG Supports the Use of Estrogen for Breast Cancer Survivors
Summary of the text:
“According to the new Committee Opinion, for women with estrogen-dependent breast cancer or a history of estrogen-dependent breast cancer, non-hormonal options for vaginal atrophy should be the first choice. However, health practitioners may now consider topical estrogen therapy for patients with a history of estrogen-dependent breast cancer who are unresponsive to non-hormonal remedies. Although there is controversy related to the risk of topical estrogen therapy and breast cancer recurrence, the Committee Opinion notes that data show there is no increased risk of cancer recurrence with the use of topical vaginal estrogen.”
Published online on American Congress of Obstetricians and Gynecologists (2016)
The Committee Opinion notes that data show there is no increased risk of cancer recurrence with the use of topical vaginal estrogen.